SEARCH

SEARCH BY CITATION

References

  • 1
    Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev2008; 21: 538582.
  • 2
    Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol2007; 5: 939951.
  • 3
    McGrath EJ, Chopra T, Abdel-Haq N et al. An outbreak of carbapenem-resistant Acinetobacter baumannii infection in a neonatal intensive care unit: investigation and control. Infect Control Hosp Epidemiol2011; 32: 3441.
  • 4
    Turton JF, Gabriel SN, Valderrey C, Kaufmann ME, Pitt TL. Use of sequence-based typing and multiplex PCR to identify clonal lineages of outbreak strains of Acinetobacter baumannii. Clin Microbiol Infect2007; 13: 807815.
  • 5
    Yang HY, Lee HJ, Suh JT, Lee KM. Outbreaks of imipenem resistant Acinetobacter baumannii producing OXA-23 beta-lactamase in a tertiary care hospital in Korea. Yonsei Med J2009; 50: 764770.
  • 6
    Higgins PG, Poirel L, Lehmann M, Nordmann P, Seifert H. Oxa-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother2009; 53: 50355038.
  • 7
    Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect2006; 12: 826836.
  • 8
    Higgins PG, Da C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother2010; 65: 233238.
  • 9
    Adams-Haduch JM, Onuoha EO, Bogdanovich T et al. Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States. J Clin Microbiol2011; 49: 38493854.
  • 10
    Nemec A, Krizova L, Maixnerova M et al. Emergence of carbapenem resistance in Acinetobacter baumannii in the Czech Republic is associated with the spread of multidrug-resistant strains of European clone II. J Antimicrob Chemother2008; 62: 484489.
  • 11
    Kresken M, Becker K, Seifert H et al. Resistance trends and in vitro activity of tigecycline and 17 other antimicrobial agents against gram-positive and gram-negative organisms, including multidrug-resistant pathogens, in Germany. Eur J Clin Microbiol Infect Dis2011; 30: 10951103.
  • 12
    Higgins PG, Lehmann M, Wisplinghoff H, Seifert H. Gyrb multiplex PCR to differentiate between Acinetobacter calcoaceticus and Acinetobacter genomic species 3. J Clin Microbiol2010; 48: 45924594.
  • 13
    Higgins PG, Wisplinghoff H, Krut O, Seifert H. A PCR-based method to differentiate between Acinetobacter baumannii and Acinetobacter genomic species 13TU. Clin Microbiol Infect2007; 13: 11991201.
  • 14
    La Scola B, Raoult D. Acinetobacter baumannii in human body louse. Emerg Infect Dis2004; 10: 16711673.
  • 15
    Vaneechoutte M, Dijkshoorn L, Tjernberg I et al. Identification of Acinetobacter genomic species by amplified ribosomal DNA restriction analysis. J Clin Microbiol1995; 33: 1115.
  • 16
    Healy M, Huong J, Bittner T et al. Microbial DNA typing by automated repetitive-sequence-based PCR. J Clin Microbiol2005; 43: 199207.
  • 17
    Saeed S, Fakih MG, Riederer K, Shah AR, Khatib R. Interinstitutional and intrainstitutional transmission of a strain of Acinetobacter baumannii detected by molecular analysis: comparison of pulsed-field gel electrophoresis and repetitive sequence-based polymerase chain reaction. Infect Control Hosp Epidemiol2006; 27: 981983.
  • 18
    Deutsches Institut für Normung (DIN). Labormedizinische Untersuchungen und in-vitro-Diagnostika-Systeme-Empfindlichkeitsprüfung von Infektionserregern und Evaluation von Geräten zur Antimikrobiellen Empfindlichkeitsprüfung, Teil 1: Referenzmethode zur Testung der in-vitro-Aktivität von Antimikrobiellen Substanzen Gegen Schnell Wachsende Aerobe Bakterien, die Infektionskrankheiten Verursachen (ISO 20776–1; 2006). Berlin: Beuth-Verlag, 2006.
  • 19
    Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. Twenty-first informational supplement. Wayne, PA: CLSI, 2011. CLSI document M100-S21.
  • 20
    Higgins PG, Lehmann M, Seifert H. Inclusion of OXA-143 primers in a multiplex polymerase chain reaction (PCR) for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents2010; 35: 305.
  • 21
    Woodford N, Ellington MJ, Coelho JM et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents2006; 27: 351353.
  • 22
    Boo TW, Walsh F, Crowley B. Molecular characterization of carbapenem-resistant Acinetobacter species in an Irish university hospital: predominance of Acinetobacter genomic species 3. J Med Microbiol2009; 58: 209216.
  • 23
    Karah N, Haldorsen B, Hegstad K, Simonsen GS, Sundsfjord A, Samuelsen O. Species identification and molecular characterization of Acinetobacter spp. Blood culture isolates from Norway. J Antimicrob Chemother2011; 66: 738744.
  • 24
    Turton JF, Shah J, Ozongwu C, Pike R. Incidence of Acinetobacter species other than A. baumannii among clinical isolates of Acinetobacter: evidence for emerging species. J Clin Microbiol2010; 48: 14451449.
  • 25
    Wisplinghoff H, Paulus T, Lugenheim M et al. Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States. J Infect2012; 64: 282290.
  • 26
    Chuang YC, Sheng WH, Li SY et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with Acinetobacter bacteremia. Clin Infect Dis2011; 52: 352360.
  • 27
    Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents2012; 39: 105114.
  • 28
    Van Looveren M, Goossens H. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect2004; 10: 684704.
  • 29
    Seifert H, Dijkshoorn L, Gerner-Smidt P, Pelzer N, Tjernberg I, Vaneechoutte M. Distribution of Acinetobacter species on human skin: comparison of phenotypic and genotypic identification methods. J Clin Microbiol1997; 35: 28192825.
  • 30
    Ben-David D, Novikov I, Mermel LA. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection?Infect Control Hosp Epidemiol2009; 30: 453460.
  • 31
    Higgins PG, Janßen K, Fresen MM, Wisplinghoff H, Seifert H. Molecular epidemiology of Acinetobacter baumannii bloodstream isolates from the United States 1995–2004 using rep-PCR and multilocus sequence typing. J Clin Microbiol2012 [Epub ahead of print] PubMed PMID: 22895032.
  • 32
    Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis2010; 16: 3540.
  • 33
    Turton JF, Baddal B, Perry C. Use of the accessory genome for characterization and typing of Acinetobacter baumannii. J Clin Microbiol2011; 49: 12601266.
  • 34
    Seifert H, Schulze A, Baginski R, Pulverer G. Plasmid DNA fingerprinting of Acinetobacter species other than Acinetobacter baumannii. J Clin Microbiol1994; 32: 8286.
  • 35
    Chen TL, Chang WC, Kuo SC et al. Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by is1006 and an ISAba3-like element to beta-lactam resistance in Acinetobacter genomic species 13TU. Antimicrob Agents Chemother2010; 54: 31073112.
  • 36
    Lee YT, Kuo SC, Chiang MC et al. Emergence of carbapenem-resistant non-baumannii species of Acinetobacter harboring a blaOXA-51-like gene that is intrinsic to A. baumannii. Antimicrob Agents Chemother2012; 56: 11241127.